Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03083782 · ClinicalTrials.gov registry record · Phase 1
Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus
A Phase 1 study, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03083782 is a Phase 1 study that has completed, run by Thomas Jefferson University. The registered enrollment target is 12 participants.
The verdict
NCT03083782, a Phase 1 study, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study aims to evaluate the pharmacokinetics (PK) of apixaban when co-administered with cyclosporine and tacrolimus in healthy volunteers. The study participants will receive apixaban alone, cyclosporine followed by apixaban and tacrolimus followed by apixaban.
Interventions
- DRUG Apixaban
- DRUG Tacrolimus
- DRUG Cyclosporine
- DRUG Apixaban alone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-04-18 |
| Est. Completion | 2017-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03083782
The ClinicalTrials.gov registry entry for NCT03083782 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Apixaban is the first listed.
NCT03083782 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03083782 about?
NCT03083782 is a clinical study titled "Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus". This study aims to evaluate the pharmacokinetics (PK) of apixaban when co-administered with cyclosporine and tacrolimus in healthy volunteers. The study participants will receive apixaban alone, cyclosporine followed by apixaban and tacrolimus followed by apixaban.
What is the current status of trial NCT03083782?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2017-04-18. Estimated completion is 2017-06-30.
What interventions are being tested in trial NCT03083782?
The interventions under investigation include: Apixaban (DRUG), Tacrolimus (DRUG), Cyclosporine (DRUG), Apixaban alone (DRUG).
Who is sponsoring clinical trial NCT03083782?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.